Ophthalmic Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecast upto2024
Overview: Ophthalmic drugs are widely used for thetreatment of eye disorders bsuch as glaucoma, conjunctivitis, cataract, dry eyes, diabetic retinopathy, and others. Development of innovative ophthalmic drugdelivery methods has aided the drug manufacturers in developing effective and advanced therapeutic tactics. American Academy of Ophthalmology has stated that, nearly 11 million individuals in the US are currectly suffering with age-related macular degeneration (AMD), while almost 10% of that population have wet AMD. Such inclinationsin eye ailments worldwide contribute to the development of the ophthalmic drugs market.
The other significant aspects that help in the improvement the market are high pervasiveness of glaucoma globally and intensification in evolution in thedevelopment of combination drugs for the glaucoma. Additionally, the changing aspects in the demography worldwide are driving the growth of the market. Nevertheless, hazard of side effects related to opthalmic drugs andloss of patent for blockbuster drugs are hampering the market growth.
Market Analysis: The “global ophthalmic drugs market” is estimated to witness a CAGR of 6.3% during the forecast period 2018–2024. The global ophthalmic drugs market is analyzed based on indication type and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the ophthalmic drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 35% of the market, with a significant contribution from the US to the market growth.
Indication Type Analysis: Based on the Indication type, the market is segmented into dry eyes, glaucoma, eye infection/inflammation, retinal disorders, and others. The market is dominated by retinal disorders and is also expected to be the fastest growing segment. However, glaucoma is the second largest segment, owing to the high prevalence of diseases and lack of awareness among the people.
Key Players: Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akron Inc., and Johnson & Johnson are the key players in the market. Shire Plc, Daiichi Sankyo, Inc., Bayer AG, F.Hoffmann-La Roche, and Sun Pharmaceuticals are the companies to watch for.
Competitive Analysis: In future, several blockbuster drugs that have dominated the morated, are expected to lose their patents. The patents of successful products accounted for over $6 billion. . Theloss of patent is the most important aspect imposing major threat to the leaders in the ophthalmic drugs market., Lupin Pharmaceuticals received US FDA approval on February 2015, for its bimatoprost ophthalmic solution 0.03%, the generic version of Lumigan. This affected the Allergan’s market. Formycon AG, a german biosimilars developing companyis currently developing biosimilar for Eylea by Regeneron Pharmaceutical’s. Allergan, meanwhile, is under the threat from Akorn, which is developing a generic version of Restasis. The release of such product is likely to generate an strong burden on the market players.
Benefits: The report provides complete details about the usage and adoption rate of ophthalmic drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
1 Industry Outlook 12
1.1 Industry Overview 12
1.1.1 Global Driver for Pharmaceutical Demand: 13
1.1.2 Pharmaceutical Spending Region Wise 13
1.1.3 R&D Pipeline in Pharmaceutical Industry 13
1.1.4 Top Pharma Drugs by Sales in 2017 ($Million) 15
1.2 Industry Trends 16
1.3 Total Addressable Market 16
2 Report Outline 18
2.1 Report Scope 18
2.2 Report Summary 18
2.3 Research Methodology 19
2.4 Report Assumptions 20
3 Market Snapshot 21
3.1 Market Definition – Infoholic Research 21
3.2 Segmented Addressable Market 21
3.2.1 Trends in the Ophthalmic Drugs Market 22
3.3 Related Markets 23
3.3.1 Bacterial Conjunctivitis Drugs 23
3.3.1.1 Trends of Bacterial Conjunctivitis Drugs Market 24
3.3.2 Contact Lenses 24
3.3.2.1 Trends of contact lens market 25
4 Market Outline 27
4.1 Ophthalmic Drugs Approved by FDA 27
4.2 Market Segmentation 28
4.3 Porter 5(Five) Forces 29
4.4 PEST Analysis 30
5 Market Characteristics 31
5.1 Market Dynamics 31
5.1.1 Drivers 31
5.1.1.1 Increasing prevalence of eye diseases 31
5.1.1.2 Increasing prevalence of cataract 32
5.1.1.3 Increasing aging population 33
5.1.2 Opportunities 33
5.1.2.1 Increasing mergers & acquisitions 33
5.1.3 Restraints 34
5.1.3.1 Complex drug development process 34
5.1.3.2 Loss of patent for blockbuster drugs 34
5.2 DRO – Impact Analysis 34
5.3 Key Stakeholders 35
6 Indication: Market Size and Analysis 37
6.1 Overview 37
6.2 Dry Eyes 38
6.3 Glaucoma 39
6.4 Eye Infection/ Inflammation 40
6.5 Retinal Disorder 41
6.6 Others 42
7 Regions: Market Size and Analysis 44
7.1 Overview 44
7.2 North America 45
7.2.1 Overview 45
7.3 Europe 47
7.3.1 Overview 47
7.4 Asia Pacific 49
7.4.1 Overview 49
7.5 Rest of the World 51
7.5.1 Overview 51
8 Competitive Landscape 52
9 Vendor Profiles 54
9.1 Allergan PLC 54
9.1.1 Overview 54
9.1.2 Business Units 57
9.1.3 Geographic Revenue 58
9.1.4 Business Focus 58
9.1.5 SWOT Analysis 59
9.1.6 Business Strategies 59
9.2 Novartis AG 60
9.2.1 Overview 60
9.2.2 Business Units 64
9.2.3 Geographic Presence 65
9.2.4 Business Focus 65
9.2.5 SWOT Analysis 66
9.2.6 Business Strategy 66
9.3 Pfizer Inc. 67
9.3.1 Overview 67
9.3.2 Business Units 69
9.3.3 Geographic Presence 70
9.3.4 Business Focus 70
9.3.5 SWOT Analysis 71
9.3.6 Business Strategies 71
9.4 Valeant Pharmaceuticals International Inc. (Bausch Health) 72
9.4.1 Overview 72
9.4.2 Business Units 75
9.4.3 Geographic Presence 76
9.4.4 Business Focus 76
9.4.5 SWOT Analysis 76
9.4.6 Business Strategy 77
9.5 Santen Pharmaceutical Co., Ltd 78
9.5.1 Overview 78
9.5.2 Business Units 80
9.5.3 Geographic Presence 81
9.5.4 Business Focus 81
9.5.5 SWOT Analysis 82
9.5.6 Business Strategies 82
9.6 Akorn Inc. 83
9.6.1 Overview 83
9.6.2 Business Focus 86
9.6.3 SWOT Analysis 86
9.6.4 Business Strategy 87
9.7 Johnson & Johnson 88
9.7.1 Overview 88
9.7.2 Business Units 91
9.7.3 Geographic Revenue 92
9.7.4 Business Focus 93
9.7.5 SWOT Analysis 94
9.7.6 Business Strategies 94
10 Companies to Watch for 96
10.1 Shire plc 96
10.1.1 Overview 96
10.1.2 Highlights 97
10.2 Daiichi Sankyo, Inc. 98
10.2.1 Overview 98
10.2.2 Highlights 98
10.3 Bayer AG 99
10.3.1 Overview 99
10.4 F. Hoffmann-La Roche (Genentech) 100
10.4.1 Overview 100
10.5 Sun Pharmaceuticals 102
10.5.1 Overview 102
10.5.2 Highlights 103
Annexure 104
Abbreviations
Tables
TABLE 1 NOVARTIS AG: OFFERINGS 60
TABLE 2 NOVARTIS AG: RECENT DEVELOPMENTS 62
TABLE 3 PFIZER INC.: OFFERINGS 68
TABLE 4 PFIZER INC.: RECENT DEVELOPMENTS 68
TABLE 5 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS 72
TABLE 6 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT DEVELOPMENTS 73
TABLE 7 SANTEN PHARMACEUTICAL CO., LTD: OFFERINGS 78
TABLE 8 SANTEN PHARMACEUTICAL CO., LTD: RECENT DEVELOPMENTS 79
TABLE 9 AKORN INC: OFFERINGS 83
TABLE 10 AKORN INC.: RECENT DEVELOPMENTS 84
TABLE 11 JOHNSON & JOHNSON: PRODUCT OFFERINGS 88
TABLE 12 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 88
TABLE 13 SHIRE PLC: OVERVIEW 96
TABLE 14 SHIRE PLC: RECENT DEVELOPMENTS 96
TABLE 15 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS 98
TABLE 16 BAYER AG: OVERVIEW 99
TABLE 17 BAYER AG: RECENT DEVELOPMENTS 99
TABLE 18 F. HOFFMANN-LA ROCHE: OVERVIEW 100
TABLE 19 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 100
Charts
CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010–2016) 12
CHART 2 R&D INVESTMENT BY TOP 10 COMPANIES ($BN) 13
CHART 3 CAUSES OF SIGHT LOSS GLOBALLY 16
CHART 4 RESEARCH METHODOLOGY OF GLOBAL OPHTHALMIC DRUGS MARKET 18
CHART 5 GLOBAL OPHTHALMIC DRUGS MARKET REVENUE, 2017-2024 ($MILLION) 22
CHART 6 OVERVIEW OF GLOBAL CONTACT LENSES USER STATISTICS 24
CHART 7 OPHTHALMIC DRUGS APPROVED BY FDA DURING 2011–2017 26
CHART 8 SEGMENTATION OF GLOBAL OPHTHALMIC DRUGS MARKET 27
CHART 9 PORTER 5 FORCES OF OPHTHALMIC DRUGS MARKET 28
CHART 10 PEST ANALYSIS OF OPHTHALMIC DRUGS MARKET 29
CHART 11 MARKET DYNAMICS – DRO ANALYSIS 30
CHART 12 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960–2060 (%) 32
CHART 13 DRO – IMPACT ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET 33
CHART 14 KEY STAKEHOLDERS 34
CHART 15 OPHTHALMIC DRUGS MARKET BY PRODUCTS TYPE SEGMENTATION, 2017-2024 ($MILLION) 36
CHART 16 OPHTHALMIC DRUGS MARKET REVENUE BY PRODUCTS TYPE, 2017–2024 ($MILLION) 37
CHART 17 DRY EYES DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 ($MILLION) 37
CHART 18 GLAUCOMA DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 ($MILLION) 39
CHART 19 EYE INFECTION/ INFLAMATION DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($MILLION) 40
CHART 20 RETINAL DISORDER DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 ($MILLION) 41
CHART 21 OTHERS OPHTHALMIC DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 ($MILLION) 42
CHART 22 OPHTHALMIC DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%) 43
CHART 23 OPHTHALMIC DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 44
CHART 24 OPHTHALMIC DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($MILLION) 46
CHART 25 OPHTHALMIC DRUGS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION) 47
CHART 26 OPHTHALMIC DRUGS MARKET REVENUE IN ASIA PACIFIC, 2017–2024 ($MILLION) 49
CHART 27 OPHTHALMIC DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION) 50
CHART 28 ALLERGAN PLC: OFFERINGS 53
CHART 29 ALLERGAN PLC: RECENT DEVELOPMENTS 54
CHART 30 ALLERGAN PLC: OVERVIEW SNAPSHOT 55
CHART 31 ALLERGAN PLC: BUSINESS UNITS 56
CHART 32 ALLERGAN PLC: GEOGRAPHIC REVENUE 57
CHART 33 ALLERGAN PLC: SWOT ANALYSIS 58
CHART 34 NOVARTIS AG: OVERVIEW SNAPSHOT 60
CHART 35 NOVARTIS AG: BUSINESS UNITS 63
CHART 36 NOVARTIS AG: GEOGRAPHICAL PRESENCE 64
CHART 37 NOVARTIS AG: SWOT ANALYSIS 65
CHART 38 PFIZER INC.: OVERVIEW SNAPSHOT 67
CHART 39 PFIZER INC.: BUSINESS UNITS 68
CHART 40 PFIZER INC.: GEOGRAPHIC PRESENCE 69
CHART 41 PFIZER INC.: SWOT ANALYSIS 70
CHART 42 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OVERVIEW SNAPSHOT 73
CHART 43 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: BUSINESS UNITS 74
CHART 44 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: GEOGRAPHICAL PRESENCE 75
CHART 45 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: SWOT ANALYSIS 75
CHART 46 SANTEN PHARMACEUTICAL CO., LTD: OVERVIEW SNAPSHOT 78
CHART 47 SANTEN PHARMACEUTICAL CO., LTD: BUSINESS UNITS 79
CHART 48 SANTEN PHARMACEUTICAL CO., LTD: GEOGRAPHIC PRESENCE 80
CHART 49 SANTEN PHARMACEUTICAL CO., LTD: SWOT ANALYSIS 81
CHART 50 AKORN INC.: OVERVIEW SNAPSHOT 83
CHART 51 AKORN INC.: BUSINESS UNITS 85
CHART 52 AKORN INC.: SWOT ANALYSIS 85
CHART 53 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 89
CHART 54 JOHNSON & JOHNSON: BUSINESS UNITS 90
CHART 55 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 91
CHART 56 JOHNSON & JOHNSON: SWOT ANALYSIS 93
CHART 57 SUN PHARMACEUTICALS: OVERVIEW 101
None
Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akron Inc., and Johnson & Johnson are the key players in the market. Shire Plc, Daiichi Sankyo, Inc., Bayer AG, F.Hoffmann-La Roche, and Sun Pharmaceuticals